Adele is commonly used in situations involving certain distressing symptoms and supports reproductive and gynecological health. This medication is primarily applied for pregnancy prevention and is also used across domains where additional symptomatic support is needed for hormone-related conditions.

Commonly, this medication is used to manage menstrual disorders such as severe cyclical pain (dysmenorrhea), excessive menstrual blood loss (menorrhagia), and irregular menstruation. It is also relevant for managing androgen-mediated physical symptoms like persistent hormonal acne and unwanted excessive hair growth (hirsutism).

“The medication assists with maintaining functional stability and supports the patient by easing distress related to symptomatic manifestations.”

The core therapeutic benefit helps patients cope more steadily with managing their reproductive planning. This also contributes to improved day-to-day comfort during symptomatic periods by easing the overall symptom load and supports more regular cycle scheduling.

---

Quick Fact: Relief for Cyclical Discomfort The medication is considered relevant in conditions characterized by periods of heightened symptoms, often used when symptoms such as severe cramping or heavy flow interfere with daily functioning.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Adele: Official Regulatory Profile

The use of Adele (Desogestrel/Ethinyl Estradiol) is primarily established for women of childbearing age after menarche who are seeking reversible contraception. Official regulatory documents define strict criteria for non-eligibility, mostly revolving around thrombotic and hormonal risk factors.

Contraindicated Populations and Conditions:

The medicine must not be used by individuals with a current or past history of venous or arterial thromboembolic disorders (e.g., deep vein thrombosis, stroke, myocardial infarction) or pre-disposing conditions like migraine with focal neurological symptoms.

Use is also contraindicated in women with known or suspected hormone-sensitive malignancies (such as breast cancer), liver tumors (benign or malignant), severe hepatic disease, or undiagnosed abnormal uterine bleeding.

Age and Physiological Restrictions:

Category	Regulatory Status
Smoking and Age	Contraindicated in women aged 35 years or older who smoke.
Pregnancy Status	Contraindicated if pregnant or pregnancy is suspected.
Lactation Status	Not recommended while breastfeeding.
Age Groups	Not indicated for use before menarche or in postmenopausal women.

Regulatory documents define these clear boundaries—such as the absolute contraindication based on thromboembolic risk—to ensure that the medicine is limited to the eligible population.

Officially Documented Interactions

Contraindicated Combinations and Restrictions

The regulatory profile for Adele (Desogestrel/Ethinyl Estradiol) formally prohibits co-administration with specific medications, including certain Hepatitis C combination regimens (Ombitasvir/paritaprevir/ritonavir pm Dasabuvir) and Fezolinetant. Co-administration with oral Tranexamic acid is also subject to regulatory restriction due to documented pharmacodynamic synergism that increases the risk of thromboembolic events. For the contraindicated Hepatitis C regimen, regulatory guidelines require that hormonal contraceptives be discontinued prior to starting the treatment and restarted approximately 2 weeks following completion of the regimen.

Pharmacokinetic and Exposure Alterations

The majority of clinically significant interactions are mediated by Hepatic Enzyme Induction from drugs like Rifampin, St. John's wort, and certain Anticonvulsants (e.g., Phenytoin, Carbamazepine), which results in decreased plasma concentrations of the contraceptive hormones. Conversely, the Ethinyl Estradiol component is documented to cause Inhibition of Metabolism for co-administered drugs like Corticosteroids and Cyclosporine, leading to their increased exposure. Additionally, official labeling notes that in patients with Hepatic Insufficiency, decreased clearance may lead to accumulation of the steroid hormones.

Catecholamine Transporter Engagement

This mechanism engages the pathways governing central arousal by both inhibiting the reabsorption and promoting the release of the key neurotransmitters norepinephrine and dopamine. This action increases the effective concentration of these mediators in the synaptic space, leading to a sustained increase in signaling within executive function pathways.

Central Nervous System Regulation

The drug's primary action is central, focusing on the prefrontal cortex and related neural circuits that govern cognitive processes and motor output. This heightened and regulated signaling leads to a physiological state of modulation of motor output and an increase in the efficiency of signal-to-noise processing necessary for attentional function.

How to Use Adele: Official Administration Guidelines

Adele is administered exclusively via the Oral route as a tablet, adhering to a precise, continuous, and cyclical regimen. All usage instructions are detailed in the official prescribing information.

Standard Dosing and Schedule

Administration follows a repetitive 28-day treatment cycle, requiring one tablet to be taken once daily at approximately the same time each day to maintain a steady dose. This schedule is typically comprised of 21 consecutive days of active hormonal tablets, followed by a 7-day period of either inert (placebo) tablets or a tablet-free interval.

Dosage forms include monophasic tablets, which provide a uniform dose of Desogestrel and Ethinyl Estradiol, and triphasic regimens, where the active component strengths vary in three distinct phases over the 21 days.

Procedural Instructions

The initiation of therapy is governed by protocols such as the Day 1 Start (first day of menses) or the Sunday Start. If the cycle begins later than Day 1, the use of an accessory barrier method is required for the first seven days.

Tablets may be taken without regard to meals or liquid. Missed-dose procedures must be followed for any dose delay exceeding 24 hours, often necessitating the immediate intake of the last missed tablet and subsequent use of a barrier method for seven days. If severe vomiting or diarrhea occurs within three to four hours of administration, the event should also be treated as a missed dose. The standard adult regimen applies to postpubertal adolescents.

Research Evidence and Clinical Study Overview for Adele (Desogestrel/Ethinyl Estradiol)

This section summarizes the research evidence and the types of studies that have been conducted to evaluate this combination oral contraceptive, according to regulatory and peer-reviewed scientific sources. The findings describe group patterns and observed changes in study populations, but research does not determine whether an individual will respond similarly.

---

1. Evidence for Use in Pregnancy Prevention

The clinical context for pregnancy prevention was studied using large-scale, multi-center trials and long-term observational settings. These studies monitored women of childbearing age, including adolescents after menarche, over defined time intervals. The main outcome examined in these studies is the statistical measure of efficacy, quantified using the Pearl Index—a statistical tool that calculates the number of accidental pregnancies per 100 women using the method for one year. Findings from trials used in regulatory contexts described patterns of accidental pregnancy rates observed in the study populations.

2. Evidence for Management of Menstrual Symptoms

The combined hormonal formulation was evaluated in research exploring outcomes related to physical discomfort, such as dysmenorrhea (painful menstruation). The evidence includes Randomized Controlled Trials (RCTs) and Systematic Reviews that focused on women with documented primary dysmenorrhea. These studies monitored outcomes related to physical discomfort, primarily measuring changes in pain severity using validated patient-reported scales and observing the frequency of needing additional analgesic medication.

3. Evidence for Addressing Hormonal Skin and Hair Conditions

This combination was studied in research exploring short-term symptom changes in women with hormonal acne and hirsutism (unwanted excessive hair growth). The evidence is derived from Comparative Studies and RCTs where the desogestrel/ethinyl estradiol combination was observed in comparison to placebo or other COC formulations. Studies monitored outcomes like acne lesion counts, hair growth scoring systems (such as the Ferriman-Gallwey Score), and changes in intermediate biomarkers like Sex Hormone-Binding Globulin (SHBG).

6. Research Gaps and What Remains Uncertain

The evidence highlights what is known—and what is still uncertain—about this medicine. Despite numerous studies, evidence quality varies across studies, leading to difficulty in synthesizing uniform conclusions across all non-contraceptive indications. Key limitations include that the sample sizes were modest in some of the specific RCTs for non-contraceptive benefits, and the comparative evidence is lacking for definitive conclusions regarding superiority against all other similar hormonal combinations. Scientific reviewers note that long-term outcomes are not well characterized for all non-contraceptive benefits.

Key Studies & References

1. Combined hormonal contraceptives for contraception

Common questions about Adele (FAQ)

Q: How quickly does Adele usually start to have an effect?

A: According to official product information, when starting this medicine, it takes at least seven days to achieve the necessary level of contraceptive protection. If therapy is initiated later than the first day of the menstrual period, a non-hormonal barrier method is recommended for the first seven days to support contraceptive effectiveness, as described in regulatory documents.

Q: Does taking Adele affect routine blood tests?

A: Yes, official safety information indicates that the hormones in this combination medicine are known to affect the results of certain laboratory tests. These include tests related to blood coagulation factors and thyroid function. Regulatory information suggests that patients undergoing lab work should disclose use of this medicine to their healthcare provider or the testing facility.

Q: Can Adele be taken by people with kidney issues?

A: While formal clinical studies detailing use in patients with kidney disease have not been conducted, official warnings advise caution. This medicine may cause fluid retention, and patients with conditions that can be worsened by fluid accumulation, such as certain renal dysfunctions, regulatory warnings specify that monitoring may be necessary.

Q: Can Adele cause changes in mood or sleep patterns?

A: Yes, regulatory documentation lists that changes in mood, including depression and nervousness, have been reported with this class of medicine. Additionally, difficulty sleeping or insomnia has been noted as a potential side effect.

Q: What kind of foods or drinks should people be aware of when taking Adele?

A: Official labeling notes that grapefruit and grapefruit juice should be avoided during use of this medicine. This is because grapefruit can change how much of the medicine is absorbed by the body, potentially altering its effect.

Q: How long do the effects of a single dose of Adele last?

A: The active components of this medicine, etonogestrel and ethinyl estradiol, have elimination half-lives ranging from approximately 24 to 37 hours at steady state. A half-life is the time it takes for half of the medicine to be cleared from the body. This duration of half-life is consistent with the product's prescribed once-daily dosing regimen.

Q: Does Adele interact with common vitamins or minerals?

A: Yes, regulatory data indicates that this medicine may decrease the intestinal absorption of certain nutrients. Specifically, it can lead to lower serum levels of folate and vitamin B-12.

Q: Can Adele be used by people with a history of seizures?

A: Official prescribing information advises caution for individuals with a history of epilepsy or seizure disorders. This medicine can cause fluid retention, which may potentially worsen conditions that are sensitive to excess fluid accumulation.

Q: Does Adele have restrictions on its use with alcohol?

A: While regulatory labels do not typically prohibit alcohol consumption, some information suggests that the medicine may alter the way the body processes alcohol. This could potentially result in alcohol staying in the body longer or lead to heightened central nervous system effects.

Q: Is it normal to feel dizzy when taking Adele?

A: Official postmarketing surveillance and clinical trial reports list dizziness as a potential side effect of this medicine. If dizziness is persistent or severe, patients are typically advised by their prescribers to seek medical guidance.

Q: Does taking Adele require regular medical monitoring?

A: Yes, official documents recommend that patients using this medicine be monitored regularly. This monitoring often includes checks for changes in cardiovascular status, blood pressure, and the possible occurrence of adverse fluid accumulation.

How to Store and Dispose of Adele

Storage of this Desogestrel and Ethinyl Estradiol combination contraceptive must strictly adhere to the conditions outlined in the official regulatory labeling.

Storage Requirement	Official Condition
Storage Temperature	Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions up to 30 C (86 F).
Protection	Keep out of the sight and reach of children. The product must be protected from freezing, light, and moisture.
Container	Store in the original container or blister packaging to preserve stability until the expiration date.

Official disposal guidance recommends using an authorized drug take-back program for unused or expired tablets. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt or coffee grounds) and placed in a sealed bag before discarding in the household trash. This product is not on the list of medicines recommended for flushing down a toilet.